Literature DB >> 18490727

IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.

Masaki Terabe1, Yutaka Tagaya, Qing Zhu, Larry Granger, Mario Roederer, Thomas A Waldmann, Jay A Berzofsky.   

Abstract

Despite recent gains in knowledge regarding CD1d-restricted NKT cells, very little is understood of non-CD1d-restricted NKT cells such as CD8(+)NK1.1(+) T cells, in part because of the very small proportion of these cells in the periphery. In this study we took advantage of the high number of CD8(+)NK1.1(+) T cells in IL-15-transgenic mice to characterize this T cell population. In the IL-15-transgenic mice, the absolute number of CD1d-tetramer(+) NKT cells did not increase, although IL-15 has been shown to play a critical role in the development and expansion of these cells. The CD8(+)NK1.1(+) T cells in the IL-15-transgenic mice did not react with CD1d-tetramer. Approximately 50% of CD8(+)NK1.1(+) T cells were CD8alphaalpha. In contrast to CD4(+)NK1.1(+) T cells, which were mostly CD1d-restricted NKT cells and of which approximately 70% were CD69(+)CD44(+), approximately 70% of CD8(+)NK1.1(+) T cells were CD69(-)CD44(+). We could also expand similar CD8alphaalphaNK1.1(+) T cells but not CD4(+) NKT cells from CD8alpha(+)beta(-) bone marrow cells cultured ex vivo with IL-15. These results indicate that the increased CD8alphaalphaNK1.1(+) T cells are not activated conventional CD8(+) T cells and do not arise from conventional CD8alphabeta precursors. CD8alphaalphaNK1.1(+) T cells produced very large amounts of IFN-gamma and degranulated upon TCR activation. These results suggest that high levels of IL-15 induce expansion or differentiation of a novel NK1.1(+) T cell subset, CD8alphaalphaNK1.1(+) T cells, and that IL-15-transgenic mice may be a useful resource for studying the functional relevance of CD8(+)NK1.1(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490727      PMCID: PMC2691148          DOI: 10.4049/jimmunol.180.11.7276

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  ITK and IL-15 support two distinct subsets of CD8+ T cells.

Authors:  Sigrid Dubois; Thomas A Waldmann; Jürgen R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

3.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 4.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens.

Authors:  T A Waldmann; Y Tagaya
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

5.  Differential regulation of T-cell growth by IL-2 and IL-15.

Authors:  Georgina H Cornish; Linda V Sinclair; Doreen A Cantrell
Journal:  Blood       Date:  2006-03-28       Impact factor: 22.113

6.  Lysosomal glycosphingolipid recognition by NKT cells.

Authors:  Dapeng Zhou; Jochen Mattner; Carlos Cantu; Nicolas Schrantz; Ning Yin; Ying Gao; Yuval Sagiv; Kelly Hudspeth; Yun-Ping Wu; Tadashi Yamashita; Susann Teneberg; Dacheng Wang; Richard L Proia; Steven B Levery; Paul B Savage; Luc Teyton; Albert Bendelac
Journal:  Science       Date:  2004-11-11       Impact factor: 47.728

7.  MyD88-dependent signaling for IL-15 production plays an important role in maintenance of CD8 alpha alpha TCR alpha beta and TCR gamma delta intestinal intraepithelial lymphocytes.

Authors:  Qingsheng Yu; Ce Tang; Sun Xun; Toshiki Yajima; Kiyoshi Takeda; Yasunobu Yoshikai
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

8.  Altered development of CD8+ T cell lineages in mice deficient for the Tec kinases Itk and Rlk.

Authors:  Christine Broussard; Christine Fleischacker; Christine Fleischecker; Reiko Horai; Madeva Chetana; Ana M Venegas; Leslie L Sharp; Stephen M Hedrick; B J Fowlkes; Pamela L Schwartzberg
Journal:  Immunity       Date:  2006-07       Impact factor: 31.745

9.  Cutting edge: TCR alpha beta+ CD8 alpha alpha+ T cells are found in intestinal intraepithelial lymphocytes of mice that lack classical MHC class I molecules.

Authors:  L Gapin; H Cheroutre; M Kronenberg
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

10.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

Authors:  J P Lodolce; D L Boone; S Chai; R E Swain; T Dassopoulos; S Trettin; A Ma
Journal:  Immunity       Date:  1998-11       Impact factor: 31.745

View more
  13 in total

1.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation.

Authors:  Eliseo F Castillo; Luis F Acero; Spencer W Stonier; Dapeng Zhou; Kimberly S Schluns
Journal:  Blood       Date:  2010-06-25       Impact factor: 22.113

3.  Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.

Authors:  Noriko Sato; Helen Sabzevari; Song Fu; Wei Ju; Michael N Petrus; Richard N Bamford; Thomas A Waldmann; Yutaka Tagaya
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

Review 4.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

5.  EBV promotes human CD8 NKT cell development.

Authors:  Yuling He; Ruijing Xiao; Xiang Ji; Li Li; Lang Chen; Jie Xiong; Wei Xiao; Yujuan Wang; Lijun Zhang; Rui Zhou; Xinti Tan; Yongyi Bi; Yan-Ping Jiang; Youxin Jin; Jinquan Tan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

6.  Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.

Authors:  Jue Hou; Qicheng Zhang; Zheng Liu; Shuhui Wang; Dan Li; Chang Liu; Ying Liu; Yiming Shao
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

7.  Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells.

Authors:  Lucy J Walker; Yu-Hoi Kang; Matthew O Smith; Hannah Tharmalingham; Narayan Ramamurthy; Vicki M Fleming; Natasha Sahgal; Alistair Leslie; Ye Oo; Alessandra Geremia; Thomas J Scriba; Willem A Hanekom; Georg M Lauer; Olivier Lantz; David H Adams; Fiona Powrie; Eleanor Barnes; Paul Klenerman
Journal:  Blood       Date:  2011-11-15       Impact factor: 22.113

8.  CD8αα Expression Marks Terminally Differentiated Human CD8+ T Cells Expanded in Chronic Viral Infection.

Authors:  L J Walker; E Marrinan; M Muenchhoff; J Ferguson; H Kloverpris; H Cheroutre; E Barnes; P Goulder; Paul Klenerman
Journal:  Front Immunol       Date:  2013-08-06       Impact factor: 7.561

9.  HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.

Authors:  Saravana Kanagavelu; James M Termini; Sachin Gupta; Francesca N Raffa; Katherine A Fuller; Yaelis Rivas; Sakhi Philip; Richard S Kornbluth; Geoffrey W Stone
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes.

Authors:  Huifeng Yu; Yongjun Sui; Yichuan Wang; Noriko Sato; Blake Frey; Zheng Xia; Thomas A Waldmann; Jay Berzofsky
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.